By Marie Rosenthal
The Infectious Diseases Society of America (IDSA) recommended against the routine use of bamlanivimab, but added a caveat that it could be considered if the patient understands the uncertainties regarding its benefits and risks.
The FDA recently granted emergency use authorizations (EUAs) to the monoclonal antibodies (mAbs)—bamlanivimab (Eli Lilly) and the cocktail casirivimab and imdevimab (Regeneron)—for use in patients with mild to moderate SARS-CoV-2 infection,